2-(6-Phenyl-1H-indazol-3-yl)-1H-benzo[d]imidazoles: Design and synthesis of a potent and isoform selective PKC-zeta inhibitor.
Trujillo, J.I., Kiefer, J.R., Huang, W., Thorarensen, A., Xing, L., Caspers, N.L., Day, J.E., Mathis, K.J., Kretzmer, K.K., Reitz, B.A., Weinberg, R.A., Stegeman, R.A., Wrightstone, A., Christine, L., Compton, R., Li, X.(2009) Bioorg Med Chem Lett 19: 908-911
- PubMed: 19097791 
- DOI: 10.1016/j.bmcl.2008.11.105
- Primary Citation of Related Structures:  
3EZR, 3EZV, 3F5X - PubMed Abstract: 
The inhibition of PKC-zeta has been proposed to be a potential drug target for immune and inflammatory diseases. A series of 2-(6-phenyl-1H indazol-3-yl)-1H-benzo[d]imidazoles with initial high crossover to CDK-2 has been optimized to afford potent and selective inhibitors of protein kinase c-zeta (PKC-zeta) ...